San Bernardino
Urological Associates

Phone: (909) 882-2973
Fax: (909) 882-2681

489 E 21st Street
San Bernardino,
CA 92404



Clinical Trial and Research Programs


Our clinical research and trial program was started in 1998 with the goal to provide our patients with the most cutting edge urological care. We have since conducted over 200 industry and federally funded studies.  

Our office has played a pivotal role in the development for Eligard (FDA approval 2002), Levaquin (2002), Levitra (2004), Vesicare (2005) and other familiar names such as Detrol, Ditropan XL, as well as the most recently approved Provenge Prostate Vaccine. We are also looking forward to the approval Cabazitaxel which is under priority review at FDA.

 Our research center is a true center of excellence making available to our  patients in Inland Empire many of the treatemnts that otherwise are available only at City of Hope, UCLA or USC. We are also collaborating closely with Johns Hopkins (Prostat and Bladder cancer), Sloan Kettering Memorial (Prostate cancer) and Mass General (Prostate Cancer).

Our research interest are listed below:

1. Prostate Cancer: multiple LHRH agonists and antagonist including Eligard.
2. Castration Resistent Prostate Cancer: including both bioactive molecules and IV chemotherapy.
    SBURC is one of the top research sites globally in protocols with IV infusion therapies.
3. Prostate Cancer Prevention
4. Bladder Cancer & Bladder Cancer Prevention
5. Overactive Bladder: Multiple protocols with Detrol LA, Ditropan XL, Medicare(Yamanouchi),
     as well as protocols with Kyowa, Schwartz and Sepracor
6. Erectile Dysfunction: Vardenafil
7. Urinary Tract Infection: Levaquin, Cirpo XR
8. Interstitial Cystitis
9. Chronic Pelvic Pain Syndrome
10. BPH
11. Testosterone Replacement

Our most up to date clinical trial programs can be found below:-



Open, Ongoing & Recent Clinical Trials 3/01/2013



Prostate Cancer, Rising PSA after Radical Prostatectomy



Sanofi-Aventis (3503) ongoing



Castration Resistent Prostate Cancer, Cabazitaxel as firstline



Sanofi, on goping


Castration Resistent Prostate Cancer, ProstaVac (vaccine trial)



BN Immunotherpeutics




Prostate Cancer and Osteoporosis, Long Term Safety Study of Denosumab



Amgen 20080537 closed


Benign Prostatic Hyperplasia (BPH), new Oral Agent


Ely Lilly I1A-MC-BPAE closed




Castration Resistent Prostate Cancer, Docetaxl with or without eIF4E Inhibitor, Phase Ib/II



 ISIS Pharmaceutical pen for enrollment


Castration Resiswtent Prostate Cancer, Cabazitaxel vs. Docetaxel



Sanofi-Aventis closed



  Castration Resistent Prostate Cancer, GTX-758


GTx Inc



  Castration Resistent Prostate Cancer, Tokai Tok 200-10




Castration Resistent Prostate Cancer, Prostavac Vaccine







             The following protocols are and some of the recently closed Studies



Prostate Cancer, Lupron vs Degarelix in post surgery and radiation patients Ferring

Hormone Refractory Prostate Cancer Early Metastatic with Provenge



Prostate cancer with Hot Flashes



Prostate Cancer, Active Surveillence



Hormone Refractory Prostate Cancer Taxane Resistent, with Cabazitaxel

Sanofi Aventis

Hormone Refractory Cancer of Prostate – Chemotherapy naïve
– Taxotere + monoclonal antibody – Phase II


 Hormone Refractory Cancer of Prostate – Chemotherapy naïve
– Taxotere + vaccine Phase III 

Cell Genesys 

 Hormone Refractory Cancer of Prostate – Chemotherapy naïve
or previously Taxotere patients – Phase II

Infinity Pharmaceutical 

Hormone Refractory Cancer of Prostate – Previously Taxotere
resistant patients – Phase III


 Hormone Refractory Cancer of Prostate – Chemotherapy naïve
or previously Taxotere patients – Phase II

Active Biotech


Metastatic Hormone refractory prostate cancer Phase I



Metastatic hormone refractory prostate cancer without pain

Cell Genesys

  Prostate Cancer with bone loss prevention GTX
  Prostate Cancer with bone loss prevention. Amgen
  Prostate Cancer prevention GlaxoSmithKline
  High Grade PIN GTX

Overactive Bladder with BPH (benign prostatic hypertrophy) – Phase IV


Overactive Bladder – PhaseII

Dainippon Sumitomo Pharma 

Overactive Bladder in Elderly Patients with Fesotrodine

Pfizer A0221049


Above is just a partial lists of over 200 trials we have worked on. 

Please call our Research Coordinator, Charity Hernandez if you have any questions or if you would like to participate in the trials @ 909-882-2973. Some of the studies do allow for patient compensations in addition to medication and medical care. Through these trial programs, we are able to deliver the most up to date urological care. Our patients have access to medications and treatment protocols that would otherwise be unavailable to them for years to come.

  Copyright © 2014 San Bernardino Urological Associates.    All Rights Reserved.   Designed & Hosted By Modern Web Studios